ELAC2 antibody
Quick Overview for ELAC2 antibody (ABIN7469339)
Target
See all ELAC2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Cross-Reactivity
- Human
-
Purification
- Purified by antigen-affinity chromatography.
-
Immunogen
- Recombinant protein encompassing a sequence within the center region of human ELAC2. The exact sequence is proprietary.
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB: 1:500-1:3000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.
-
Comment
-
Positive Control: Jurkat , Raji , NCI-H929
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.73 mg/mL
-
Buffer
- 1XPBS ( pH 7), 20 % Glycerol, 0.025 % ProClin 300
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
-
-
- ELAC2 (ElaC Homolog 2 (ELAC2))
-
Alternative Name
- ELAC2
-
Background
-
Synonyms: elaC ribonuclease Z 2 , COXPD17 , ELC2 , HPC2
Background: The protein encoded by this gene has a C-terminal domain with tRNA 3′ processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq]
-
Molecular Weight
- 92 kDa
-
Gene ID
- 60528
-
UniProt
- Q9BQ52
Target
-